PB15007_brochure

T H E 2 n d a n n u a l W O R LD C O N G R E S S S U M M I T O N
Oncology Market Access
under New Payment and Delivery Models
Multi-Stakeholder Perspectives on Navigating the Evolving Landscape to Optimize Market Share
March 23-24, 2015 • Sheraton Philadelphia University City Hotel • Philadelphia, PA
SAVE UP TO $400 WHEN YOU REGISTER BY January 23, 2015!
Featuring Oncology Experts from Various Stakeholder Groups:
Organized by:
Visit www.worldcongress.com/oncology for full faculty listing and comprehensive agenda.
Jax Ferguson
Director, Oncology
Corporate Affairs
Eli Lilly &
Company
Scott R. Steuart
Vice President,
Market Access,
National Specialty
Accounts
Sanofi
C. Lyn Fitzgerald
Vice President,
U.S. and Global
Development
National
Comprehensive
Cancer
Network
Ted Okon
Executive Director
Community
oncology
alliance
Michael
Kolodziej, MD
National
Medical Director,
Oncology Solutions
aetna
Brian B.
Kiss, MD
Vice President,
Healthcare
Transformation
blue cross
blue shield
of Florida
Karen K.
Fields, MD
Senior Member,
Medical Oncology
Member Director,
Strategic Alliances
Moffitt cancer
center
Michael Spigel ,
MHA, PT
President,Chief
Operating Officer
brooks
Rehabilitation
Educational
Underwriter:
Media Partners:Cocktail Reception
Sponsor:
Pharmaceutical Executives: influencers:
Hospital and Physician Executives:Health Plan Executives:
www.worldcongress.com/oncology | 800-767-9499 | wcreg@worldcongress.com
Patient

Why attend?
• Hear from a variety of stakeholders including
payers, providers, and patient organizations
• Takeaway key learnings from successful
ACOs and initiatives
• Explore perspectives on the benefits and
shortcomings of different distribution models
• Address recent updates on clinical
guidelines and government policy
• Evaluate the future of the industry with the
rise of personal medicine and introduction
of biosimilars in the market
WHO SHOULD ATTEND?
From Pharmaceutical and
Biotech Companies
Vice Presidents, Directors, and Managers of:
• Oncology Reimbursement and Pricing
• Oncology National Accounts
• Payer Strategy/Marketing
• Oncology Managed Markets and Market Access
• Oncology Marketing
• Pipeline Planning
This Meeting Also Benefits:
• Commercialization and Market Access Consultants
• Oncology Marketing and Commercialization
Solution Providers
• Specialty Pharmacies and Distributors
• Health Plan Executives
RESERVE YOUR SEAT TODAY. The earlier you book, the more you save.
See back page for details or call 800-767-9499 for more information.
W H Y YO U
S H O U L D
S P O N S O R
POSITION
your company
as a leading
solutions and
service provider
MEET
your market
SHOWCASE
new technology
innovations
INCREASE
brand awareness
GENERATE
leads and new
business
DEVELOP
new and
current client
relationships
To inquire about Sponsorship and Executive Networking Opportunities, Contact
David Capobianco, Vice President, Business Development, World Congress • Call 781-939-2635 or email David.Capobianco@worldcongress.com
March 23-24, 2015 • Sheraton Philadelphia University City Hotel • Philadelphia, PA

Day One — Monday, March 23, 2015
7:30 am –
8:30 am
Summit Registration and Morning Coffee
8:30 am –
8:45 am Chairperson’s Welcome and Opening Remarks
8:45 am –
9:30 am Address New Oncology Clinical Guidelines and How Various Stakeholders Plan to Use Them
Consider NCCN’s most recent updates on treatment protocol with an eye towards how payers and providers plan on incorporating it into their strategy,
and how bio/pharmaceutical manufacturers can plan strategies around this.
• Hear about the NCCN guideline changes and updates
* Consider how these shifts impact the landscape for use across the spectrum of stakeholders
• Recognize outcomes-based evidence as the driver for reimbursement, coverage policy, and improved clinical care
• Address the change in guidelines from fee-for-service to fee-for-value, promoting value-based reimbursement among payers
C. Lyn Fitzgerald
Vice President,
U.S. and Global Development
National Comprehensive Cancer Network
Al B. Benson, III, MD
Professor of Medicine,
Robert H. Lurie Comprehensive Cancer Center
Northwestern University
9:30 am –
10:15 am Understand How Payer Management of the Cost of Cancer Care is Evolving and the Impact on
Market Access
Due to a wide number of factors, there has been a shift in the way cancer care is provided as well as how it is paid for. Payers have made the switch to
value-based care which significantly impacts and changes bio/pharmaceutical companies’ strategies for getting their therapies to patients. PBMs are
also expanding the exclusions of high priced drugs from their formularies in an effort to provide cost-effective solutions for their clients. Learn about this
shift in strategy and how manufacturers can better align with payers and PBMs.
• Understand the shift to evidence-based treatment programs as a means to provide better care at a lower cost
• Address the impact of payers incentivizing physicians to adhere to pathways
• Understand payer trends around cost of care in relation to patient outcomes
• Identify how these payer decisions impact bio/pharmaceutical market access strategies
• Recognize how manufacturers’ pricing strategies should match up with payer and provider expectations
Jonathan Harding, MD
Chief Medical Officer, Senior Products Division
Tufts Health Plan
Michael Kolodziej, MD
National Medical Director, Oncology Solutions
Aetna
10:15 am –
10:45 am
Networking and Refreshment Break
10:45 am –
11:30 am Explore the Managed Care Perspective to Develop Best Practices in Payer-Manufacturer Relationships
• Identify drivers and barriers to successful relationships between managed care and manufacturers of oncology agents
• Explore evolving approaches to managing high-cost oncologics as costs of agents rise and combination therapies become more of the norm
• Pinpoint the perceptions, attitudes, and behaviors that drive successful plan-manufacturer relationships
• Learn why payers believe that their favorite companies, brands, and account teams provide superior value
Roger Green
President, Chief Executive Officer
RG+A
11:30 am –
12:15 pm Understand Changes in Health Insurance Design
• Address the general movement to a high deductible insurance design
• Identify strategies for stakeholder collaboration on insurance design to lift the financial burden off of the patient and minimize “financial toxicity”
• Discuss the shift from defined-benefit to defined-contribution, and how that impacts cost of care for the patient
Shelley Fuld Nasso
Chief Executive Officer
National Coalition for Cancer Survivorship
12:15 pm –
1:30 pm
Luncheon
What you get with your webcast registration:
• Real-time footage directly to your computer
• Ability to participate in live Q&A sessions
• No travel or hotel costs
• Benefit of being able to implement strategies and best practices
as they are being presented
Can’t travel
to Philadelphia?
Join us via the
Live-Streaming
Webcast!

Day One — Monday, March 23, 2015 (Continued)
1:30 pm –
2:15 pm Evaluate the Impact of the Change in the Site of Cancer Care
Over the past eight years, many independent oncology practices have closed treatment clinics and have been acquired by hospitals. This has led to
access issues and especially has had a significant impact on the cost of cancer treatment for private insurers, Medicare, and patients.
• Understand why this shift is occurring and discover how payers and providers are reacting to the changing landscape
• Explore how the shift has impacted cancer treatment costs and patient care
• Forecast how government policy and payer actions may influence the changing landscape of cancer care going forward
Ted Okon
Executive Director
Community Oncology Alliance
2:15 pm –
3:15 pm Explore the Emergence of Oncology Medical Homes
The implementation of the ACA and ACOs has changed the way payers and oncologists reimburse and prescribe drugs. Explore how the shift to accountable
care has created a greater focus on evidence-based outcomes in relation to cost-effectiveness and the impact that this has on all stakeholders.
• Understand the nuances of a variety of new models such as Oncology Patient Centered Medical Homes, Oncology ACOs, etc.
• Explore how these new models are changing the roles of different stakeholder groups, including a shift in which stakeholders are ultimately impacting
coverage determinations
• Evaluate the payer outlook on pathways and ACO programs and discuss challenges faced by payers and providers
• Hear about key leanings and outcomes of the Florida Blue Cross Blue Shield and Moffitt Cancer Center Oncology focused Accountable Care Arrangement
Karen K. Fields, MD
Senior Member, Medical Oncology
Medical Director, Strategic Alliances
Moffitt Cancer Center
Brian B. Kiss, MD
Vice President, Healthcare Transformation
Blue Cross Blue Shield of Florida
3:15 pm –
3:45 pm
3:45 pm –
4:30 pm Understand the Impact of Bundled Payments
Some organizations have reduced costs and maintained or enhanced the quality of care through the implementation of bundled payments.
• Understand what attributes of a bundle make them successful for all stakeholders involved including manufacturers
• Hear about some case examples of successful bundled payment models
• Examine lessons from BPCI including the challenges and keys to success
• Discuss cancer bundles and CMMI’s Oncology Care Model
Michael Spigel, MHA, PT
President, Chief Operating Officer
Brooks Rehabilitation
Jessica Walradt, MS
Senior Payment Reform Specialist
Association of American Medical Colleges
4:30 pm –
5:15 pm Explore the Evolving Medicaid and 340B Climate
The ACA has increased Medicaid enrollment over the past year through changes in eligibility, process, and increased outreach. This has posed many
challenges for manufacturers who must now change their pricing strategies to fit a new model. 340B pricing which allows eligible hospitals to receive
discounted rates for drugs has also made a large impact on the industry, wiping out 40-50% of product revenue.
• Discuss Medicaid expansion, what it means for stakeholders, and strategies for managing the new pricing system
• Explore the transition from State Medicaid to Managed Medicaid programs and how this may impact access to oncolytics
• Identify 340B trends — How it was designed versus how it is currently used
* Discuss HRSA’s new guidance on key 340B policy issues after the withdrawal of the mega rule
* Discuss updates on the orphan drug exclusion
Tony Zappa
Vice President, Contract Pharmacy Operations
Wellpartner
5:15 pm –
6:15 pm
Cocktail and Networking Reception Hosted by:
"The World Congress Oncology Market Access Summit was one of the few conferences I have attended where I walked away with a wealth of knowledge
and valuable contacts for better understanding how delivery system reform, advancements in therapeutics, and reimbursement initiatives can align better.”
– Kavita Patel, MD, MS, Managing Director of Delivery System Reform and Clinical Transformation, The Brookings Institution

Day two — Tuesday, March 24, 2015
8:00 am –
8:30 am
Morning Coffee
8:30 am –
8:45 am Chairperson’s Welcome and Review of Day One
8:45 am –
9:30 am Explore the Employer Perspective on the Management of Cancer Care as Part of Benefits Programs
As the insurance market shifts, employers are another integral stakeholder group in the benefits discussion surrounding the treatment and cost of
cancer care.
• Explore different approaches to include affordable oncology treatments in employee benefit offerings
• Discuss the employer focus on supportive care measures and increased quality of life
• Understand what employers are looking at when choosing health plans
Thought Leader TBA
9:30 am –
10:15 am Explore the Benefits and Shortcomings of Different Drug Distribution Models
• Explore the benefits and shortcomings of different specialty distribution models
• Discuss how these models impact cost and delivery of care
• Evaluate the downsides to a limited or closed network, including the negative perceptions by providers and patients
• Explore the growing use specialty pharmacy and high-touch services
Scott R. Steuart
Vice President, Market Access, National Specialty Accounts
Sanofi
10:15 am –
10:45 am
10:45 am –
11:30 am Discover How Value Added Services and Access Considerations Differentiate Oncology Products
in the Market
With increased market competition in the oncology space, manufacturers must find ways to differentiate their products and add value through increased
customer service touch points. Discuss some potential methods and options for increasing the customer engagement and access to treatment.
• Identify what new services are essential and valuable to patients
• Consider the impact that access to care has on treatment decisions
Jax Ferguson
Director, Oncology Corporate Affairs
Eli Lilly & Company
Bill Goodson
Deputy Director Pricing, Reimbursement and Patient Assistance
Bayer HealthCare, LLC
11:30 am –
12:15 pm Leverage Real-World Data as a Mechanism to Enhanced Access
Data has become an essential piece of payer and provider acceptance of products. Explore the manufacturer’s role in collecting, analyzing, and reporting
real-world outcomes data to other stakeholder groups.
• Identify ways that manufacturers can demonstrate product value by using real-world data
• Provide relevant evidence to the target audience, differentiating between payers and providers
• Turn data into meaningful and tangible messages for stakeholders
Yanni Hao, PhD
Director, U.S. Oncology Health Economics
and Outcomes Research
Novartis Pharmaceuticals Corporation
Dalia Mahmoud
Senior Director, Head, Hematology and Oncology,
Global Pricing and Market Access
Celgene
12:15 pm –
1:30 pm
Luncheon
"World Congress' Oncology Market Access meeting provided many thought-provoking ideas from a wide range of very senior leaders. The balance
between the provider and payer perspective helped round out perspectives on many emerging trends. I definitely left the meeting with new thinking
on what may happen in the next few years regarding oncology market access."
– Susan Weber, Director, Brand Access Analysis, Health Strategies Group

Day two — Tuesday, March 24, 2015 (Continued)
1:30 pm –
2:15 pm Personalized Medicine and Biomarker Targeting — Consider the Major Challenges Around Cost and
Reimbursement for Oncology Treatments
Targeted treatments have already achieved success through use of diagnostic testing to pinpoint which individuals are eligible for specific therapies, and
will continue to become more personalized in the future. Personalized medicine allows doctors to prescribe the medicine that is most likely to work for a
certain patient and their specific tumor. Discuss the major challenges around cost and reimbursement for these specialized treatments.
• Evaluate the payer perspective on personalized therapies and their willingness to manage high cost oncolytics
• Discuss how these therapies may be measured for value
• Explore different pricing models that encourage reimbursement and prescription
• Examine ways that relevant stakeholders can align objectives to provide better patient outcomes
Laura Housman, MPH, MBA
Senior Vice President, Chief Commercial Officer
Molecular Health
Ralph Riley, MBA
Global Leader, Health Economics and Pricing
Janssen Diagnostics
2:15 pm –
3:00 pm Address the Impact of Biosimilars on the Oncology Market
Biosimilars or follow-on biologics are expected to come to the U.S. market within the year, and at a lower price. Due to the high cost of oncology
therapies, these lower cost alternatives could pose as an affordable option for many patients. However there are many uncertainties around these
products, including the acceptance by payers and providers, and the impact on the market share of branded products. While there may not be
answers to many of these questions right now, each stakeholder group is considering how the introduction of these products could change the
oncology landscape.
• Explore the effect of regulatory guidelines for biosimilars
* How will substitution, interchangeability, and abbreviated approval pathways impact branded oncology therapies?
* Will there be a different overall attitude in the U.S. versus the EU for biosimilars?
• Assess biosimilar viewpoints within the payer and provider context
• Consider what the cost differential might be in order to encourage prescription and even non-medical switching
• Explore whether commercial and government payers including CMS could cover these therapies
Bruce A. Feinberg
Vice President, Chief Medical Officer
Cardinal Health Specialty Solutions
3:00 pm Close of Summit
RESERVE YOUR SEAT TODAY. The earlier you book, the more you save.
See back page for details or call 800-767-9499 for more information.
W H Y YO U
S H O U L D
S P O N S O R
POSITION
your company
as a leading
solutions and
service provider
MEET
your market
SHOWCASE
new technology
innovations
INCREASE
brand awareness
GENERATE
leads and new
business
DEVELOP
new and
current client
relationships
CONSIDER A SPONSORSHIP PACKAGE
• Present to Key Players in Your Target Market • Take Advantage of 1-on-1 Sponsor/Attendee Meetings Facilitated On-Site
CAPTURE A TRUE ROI Through Sponsorship of the Following:
Agenda Thought Leadership • Networking Cocktail Reception • Breakfast Symposia • Luncheon • Executive Networking Breaks
To inquire about Sponsorship, Exhibit, and Executive Networking Opportunities, Contact
David Capobianco,Vice President, Business Development, World Congress • Call 781-939-2635 or email David.Capobianco@WorldCongress.com
"I thoroughly enjoyed participating in the Oncology conference.All aspects were extremely well-organized and the registrants were extremely interested and
engaged in the discussion of measuring outcomes as they relate to health care reimbursement in the future. I also made some great contacts with some of
the registrants after my presentation which is always helpful. I was pleasantly surprised and learned a lot."
– Thomas Feeley, MD, Head, Institute for Cancer Care Innovation, MD Anderson

Registration Fee: Register By
1/23/2015
Register By
2/13/2015
Register By
3/24/2015Standard
Conference $ 2395.00 $ 2595.00 $ 2795.00
Pharma / Biotech
Conference $ 1595.00 $ 1795.00 $ 1995.00
Hospital Health systems
Conference $ 1095.00 $ 1195.00 $ 1295.00
Health Plans
Conference $ 1395.00 $ 1595.00 $ 1795.00
Webcast
Webcast $ 1595.00
Webcast Plus Flash Drive $ 1694.00
Webcast Archive on Flash Drive $ 1595.00
Fee for conference includes welcome coffee, lunch, reception,
refreshments, and web-based conference documentation available pre-
and post-event, accessible through password-protected website. Checks in
U.S. funds drawn from U.S. bank payable to: WC Research Inc. No personal
checks accepted. Verification may be required for rate approvals.
SPECIAL TEAM DISCOUNTS: With so much great
content, you can’t possibly cover it alone. Sign up
your team and save. Find out more about special
group package discounts by calling 800-767-9499
or emailing wcreg@worldcongress.com.
Participant Substitution and Cancellations:
Your registration may be transferred to a member of your organization
up to 24 hours in advance of the conference. Cancellations received
in writing on or before 30 days prior to the start of the event will be
refunded, less a $395 administrative charge. No refunds will be made
after this date; however, the registration fee less the $395 administrative
charge can be credited to another World Congress conference if you
register within 6 months from the date of this conference. In case of
conference cancellation,World Congress’ liability is limited to refund of
the conference registration fee only. World Congress reserves the right
to alter this program without prior notice.
Satisfaction guaranteed: World Congress stands behind the
quality of its conferences. If you are not satisfied with the quality of
the conference, a credit will be awarded towards a comparable World
Congress conference of your choice.
Best Value
PRSRT STD
U.S. Postage
PAID
Gallery
World Congress
500 West Cummings Park, Suite 5200
Woburn, MA 01801
PB15007
SAVE UP TO $400 WHEN YOU REGISTER BY JANUARY 23, 2015!
Reserve your seat today to learn the latest
strategies from top health plans, cancer centers,
pathways, pharmaceutical companies, and more.
M a r c h 2 3 - 2 4 , 2 0 1 5 • S h e r a t o n P h i l a d e l p h i a U n i v e r s i t y C i t y H o t e l • P h i l a d e l p h i a , PA
Venue:
Sheraton Philadelphia University City Hotel
3549 Chestnut Street
Philadelphia, Pennsylvania 19104
Phone: 215-387-8000
www.PhiladelphiaSheraton.com
Room Rate: $149 • Cut-off Date: 2/27/2015
Please mention WC Research/World Congress
when registering to receive this special rate!
WEBSITE
WorldCongress.com/
Oncology
Register Now! E-MAIL
wcreg@worldcongress.com
ATTN Mail Room: If undeliverable
please forward to Oncology
Commercialization Teams
PHONE
800-767-9499
781-939-2400 outside the U.S.
@wrldhealthcare
#WConcology2015
Hear from:Hear from: Featured topics include:Featured topics include:
• Aetna • Celgene
• Eli Lilly Company • Florida Blue
• Moffitt Cancer Center • Sanofi
• Janssen • Molecular Health
• National Coalition for Cancer Survivorship
• Community Oncology Alliance
• Cardinal Health Specialty Solutions
• Novartis Pharmaceuticals Corporation
• Brooks Rehabilitation
• Association of American Medical Colleges
• Wellpartner
• New Oncology Clinical Guidelines and How
Various Stakeholders Plan to Use Them
• The Emergence of Oncology Medical Homes
• How Payer Management of the Cost of
Cancer Care is Evolving and the Impact
on Market Access
• The Impact of the Change
in the Site of Cancer Care
• Real-World Data as a
Mechanism to Enhanced Access

PB15007_brochure

Recommended

Recommended

More Related Content

What's hot

What's hot (20)

Viewers also liked

Viewers also liked (20)

Similar to PB15007_brochure

Similar to PB15007_brochure (20)

PB15007_brochure